Senseonics stock rises ~5% after hours on Q2 results beat, unchanged FY revenue guidance

Aug. 09, 2022 5:17 PM ETSenseonics Holdings, Inc. (SENS)By: Anuron Mitra, SA News Editor3 Comments

Rolled newspaper with the headline Quarterly Results


  • Shares of Senseonics (NYSE:SENS) gained 5.4% to $1.96 in Tuesday postmarket trading, after the company reported Q2 results that beat estimates and kept it FY 2022 revenue guidance unchanged.
  • Germantown, Md.-based SENS is medical device company catering to diabetics. Its flagship product is the Eversense E3 continuous glucose monitoring system.
  • SENS posted Q2 GAAP EPS of $0.22 which beat estimates by $0.26. Its Q2 revenue of $3.7M rose 12.1% Y/Y and beat by $0.12M.
  • The company also reaffirmed its FY 2022 global net revenue guidance of $14M to $18M. The consensus revenue estimate is $16.83M.
  • Last week, SENS said it had received a positive coverage decision for the Eversense E3 system from Anthem, now called Elevance Health (ELV), added over 45M covered lives for the system.
  • Investors reacted favorably to the news and saw the decision as a revenue booster. SENS stock closed more than 20% higher on both Aug. 3 and 4.

Recommended For You

Comments (3)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.